Clinical Trials and Research News Weekly Roundup | FDA Greenlight for Ivermectin Clinical Trial

Sep 21, 2020 | Digital Media, Video, Weekly Roundup

TrialSite News Ivermectin

 

Southern California Research Institute Receives FDA Greenlight for Ivermectin Clinical Trial: California’s ProgenaBiome recently received the greenlight from the U.S. Food and Drug Administration (FDA) for two Phase 2 clinical trials involving investigational therapies targeting COVID-19: one of them based on hydroxychloroquine and the other ivermectin. With approved investigational new drug (IND) applications, a dynamic and accomplished California gastroenterologist andy principal investigator, Dr. Sabine Hazan, and team now prepare to conduct important studies investigating two possible economical therapies for treating SARS-CoV-2, the virus behind the COVID-19 pandemic. https://www.trialsitenews.com/souther…
 
Experts Debate While West Texas Doctor Stands Ground on Inhaled Steroid for COVID-19: On July 14, we published “West Texas Doctor Bartlett: Is He on to a ‘Silver Bullet’ with Use of Off-Label Inhaled Steroid as COVID-19 Treatment?” This doctor is using budesonide, an inhaled steroid asthma medicine as a key treatment for COVID-19. On August 19, the Texas Standard offered an update. They note that Dr. Bartlett has been using budesonide for COVID-19 patients for months. The doctors notes that the medicine is proven safe, inexpensive, and easily available. The doctor says he stumbled on the idea while working an ER shift in March. “I laid down for a cat nap between patients. I woke up convinced that God had given me a winning strategy. And a week later, I had to try it out on my first two patients, and for every patient it’s working,” Bartlett has said. Dr. Bartlett has an emergency clinic at Lubbock, Texas, and, “privileges at three hospitals in west Texas”; upon being asked, he did not say how many people he has treated, “but he estimated that he and other doctors have prescribed budesonide to over 400 patients.” https://www.trialsitenews.com/experts…
 
Reported SUSAR Delays AstraZeneca AZD1222 Phase 3 Trial: Pressure Mounts as this Vaccine Could be the Nov Candidate: By Sept 9 AstraZeneca reports in a statement to various news sources that an apparent suspected serious adverse reaction (SUSAR) occurred in the United Kingdom with AZD1222 during the Phase 3 clinical trial. The late stage studies clinical trial was put are on hold, as TrialSite reported earlier on Tuesday, September 8, around the world due to a serious side effect linked to the administration of the experimental vaccine. This delay is notable as AZD1222 is the subject of serious chatter concerning its potential as an early emergency use authorization (EUA) target https://www.trialsitenews.com/reporte…
 
University of Louisville CPM & RedHill Demonstrate Opaganib Inhibits SARS-CoV-2 In Vitro in Human Lung Tissue: RedHill Biopharma Ltd. (Nasdaq: RDHL) (“Redhill”) based in Israel and Raleigh, North Carolina, reported recently that working in collaboration with University of Louisville Center for Preventive Medicine, opaganib1 demonstrated potent inhibition of SARS-CoV-2, actually achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue. In the meantime, the Israeli and American firm continues two Phase 2/3 clinical trials targeting hospitalized COVID-19 patients with pneumonia. They seek funding from the U.S. government, possibly via Operation Warp Speed, to accelerate completion to emergency use authorization should the data justify. https://www.trialsitenews.com/univers…
SHOW LESS
 
 
 
 

0 Comments

Pin It on Pinterest